(Reuters) – Moderna Inc said on Monday it expected to record sales of about $18.5 billion in 2022 from contracts for its COVID-19 vaccines, about $3.5 billion for potential additional purchases including booster candidates updated for variants.
The company had forecast in November that its sales could be in the range of $17 billion to $22 billion in 2022.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)
